![November/December 2024: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons](https://icap.columbia.edu/wp-content/uploads/Journal-Club-Nov-Dec-2024-1080x675.jpg)
Peru
![November/December 2024: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons](https://icap.columbia.edu/wp-content/uploads/Journal-Club-Nov-Dec-2024-1080x675.jpg)
![July/August 2024: Implementing an Antimicrobial Stewardship Program in an Oncology Center in Lima, Peru: A Model for Low-and Middle-Income Countries](https://icap.columbia.edu/wp-content/uploads/Journal-Club-JulAug-2024-1080x675.jpg)
July/August 2024: Implementing an Antimicrobial Stewardship Program in an Oncology Center in Lima, Peru: A Model for Low-and Middle-Income Countries
Article and Study Summary: Article Implementing an Antimicrobial Stewardship Program in an Oncology Center in Lima, Peru: A Model for Low-and Middle-Income Countries. Published in: Open Forum Infectious Diseases. 2024; 4(8):...![September 2023: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection](https://icap.columbia.edu/wp-content/uploads/JC-2023-photo-973x675.jpg)
September 2023: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Article and Study Summary: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection Published in: N Engl J Med. 2023;389(8):687-699. https://www.nejm.org/doi/full/10.1056/NEJMoa2304146 Authors: Steven K. Grinspoon, M.D., Kathleen V. Fitch, M.S.N., Markella V....Programmatic Support Award (PSA)
Building on over 15 years of partnership between ICAP at Columbia University, PEPFAR, and CDC, the Programmatic Support Award provides rapid, flexible technical support to accelerate evidence-based HIV prevention and treatment program implementation and align health...![May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis](https://icap.columbia.edu/wp-content/uploads/0-3-e1622128820264-1080x675.png)